Products for cold storage of embryos approved in Canada

Products for cold storage of embryos approved in Canada

Vitrolife has obtained approval from Health Canada for two new products within
the fertility area. The products are used for so-called vitrification, rapid
freezing and thawing of blastocysts (embryos day 5-7 after fertilization).

”Products for vitrification involve considerable technological progress and open
up new opportunities within IVF treatment”, says Vitrolife's CEO, Magnus
Nilsson. ”We are very happy to have had these first two products approved and
now we are continuing to work on getting more products for vitrification out on
to the market.”

The two vitrification products that Vitrolife has obtained approval for are
RapidVit™ Blast och RapidWarm™ Blast. Vitrification involves very rapid
freezing, to prevent the formation of ice crystals that otherwise can cut the
cells apart. In IVF fertilization more than 10 oocytes are often taken from the
woman. A number of these are fertilized. The oocytes that are fertilized but not
put back in the woman can then be kept in cold storage. It has been seen in the
use of the vitrification method that survival increases considerably after cold
storage. The chance of achieving a good cumulative pregnancy frequency thereby
increases for the woman, without her having to undergo new hormone treatment and
the removal of more oocytes.     



December 5, 2007
Kungsbacka, Sweden 

Magnus Nilsson
CEO







Queries should be addressed to: 
Magnus Nilsson, CEO, phone +46 31 721 80 00 or +46 708 22 80 61.
Anna Ahlberg, CFO, phone +46 31 721 80 13 or +46 708 22 80 13.


________________________________________________________________________________
_________
Vitrolife is a global biotechnology/medical device Group that works with
developing, manufacturing and selling advanced products and systems for the
preparation, cultivation and storage of human cells, tissue and organs. The
company has business activities within three product areas: Fertility,
Transplantation and Stem Cell Cultivation. The Fertility product area works with
nutrient solutions (media) and advanced consumable instruments such as needles
and pipettes, for the treatment of human infertility. The Transplantation
product area works with solutions and systems to maintain tissue in optimal
condition outside the body for the required time while waiting for
transplantation. The Stem Cell Cultivation product area works with media and
instruments to enable the use and handling of stem cells for therapeutic
purposes. 
     Vitrolife today has approximately 140 employees and the company's products
are sold in more than 80 markets. The head office is in Kungsbacka, Sweden, and
there are subsidiaries outside Gothenburg, Sweden and in Denver, USA. The
Vitrolife share is listed on the OMX Nordic Exchange's Nordic Small Cap list.
________________________________________________________________________________
_________
Vitrolife AB (publ), Faktorvägen 13, SE-434 37 Kungsbacka, Sweden. Corporate
identity number 556354-3452.
Tel: +46 31 721 80 00. Fax: +46 31 721 80 90. E-mail: info@vitrolife.com.
Homepage: www.vitrolife.com.

This is a translation of the Swedish version of the press release. When in
doubt, the Swedish wording prevails.